Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 80,600 shares, a growth of 258.2% from the December 31st total of 22,500 shares. Based on an average daily trading volume, of 358,600 shares, the short-interest ratio is presently 0.2 days. Currently, 4.6% of the company’s stock are sold short.
Avenue Therapeutics Stock Down 1.5 %
Shares of NASDAQ ATXI traded down $0.02 during mid-day trading on Thursday, reaching $1.32. 177,001 shares of the company were exchanged, compared to its average volume of 1,158,499. The firm has a 50-day moving average of $1.86 and a 200 day moving average of $2.29. Avenue Therapeutics has a 1 year low of $1.26 and a 1 year high of $15.00. The stock has a market cap of $2.71 million, a price-to-earnings ratio of 0.07 and a beta of -0.27.
Institutional Trading of Avenue Therapeutics
An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC purchased a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned 1.17% of Avenue Therapeutics as of its most recent filing with the Securities and Exchange Commission. 17.34% of the stock is currently owned by institutional investors and hedge funds.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- Energy and Oil Stocks Explained
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- 3 Stocks to Consider Buying in October
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
